Selank — Apex Research Reference

01 / IDENTITY

Compound Profile

7

AMINO ACIDS

~0.86

kDa MW

SC/IN

ROUTE

~1–2h

HALF-LIFE

SEQUENCE

Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)

CLASSIFICATION

Synthetic heptapeptide analog of tuftsin (naturally occurring immunomodulatory tetrapeptide Thr-Lys-Pro-Arg). The Pro-Gly-Pro extension dramatically stabilizes the molecule and adds CNS-active anxiolytic properties not present in native tuftsin.

MECHANISM

Modulates serotonin, dopamine, and GABA neurotransmitter systems. Increases BDNF (brain-derived neurotrophic factor). Stabilizes and upregulates mRNA for GABA-A receptors. Enkephalinase inhibition → increases endorphin availability. Reduces IL-6 neuroinflammation. Crosses blood-brain barrier effectively.

DEVELOPER

Institute of Molecular Genetics (IMGR) and Institute of Pharmacology, Russian Academy of Sciences. V.V. Semenova and T.A. Gudasheva led development in 1980s–1990s.

REGULATORY STATUS

Approved anxiolytic medication in Russia (since 2002). Prescription drug in Russia for generalized anxiety disorder. Not FDA-approved; research compound in Western markets.

VIAL SIZE

10mg lyophilized powder

02 / RESEARCH HISTORY

Development Timeline

1980s

Russian neuroscientists at IMGR seek a non-benzodiazepine anxiolytic without sedation, addiction, or cognitive impairment — the main failures of the benzo drug class. Tuftsin (Thr-Lys-Pro-Arg) — a natural immunomodulatory peptide from the spleen — is identified as having mild CNS activity. Work begins to extend and stabilize tuftsin for anxiolytic application.

1992

Selank (TKPRPGP) synthesized — tuftsin with a C-terminal Pro-Gly-Pro extension. The extension prevents rapid enzymatic degradation, extends CNS activity, and critically adds anxiolytic properties not present in the parent tuftsin molecule. Animal studies confirm dose-dependent anxiolytic effects comparable to diazepam without sedation.

1994–2002

Phase I, II, and III clinical trials in Russia. Primary indication: generalized anxiety disorder (GAD). Trials demonstrate efficacy equal to traditional anxiolytics (phenazepam class) with superior safety profile — no sedation, no addiction, no cognitive impairment. Cognitive enhancement as secondary finding surprises researchers. Approved as prescription medication in Russia 2002.

2008–2014

Selank's mechanism of action studied in detail. BDNF upregulation discovered — unique among anxiolytics. Serotonin transporter mRNA modulation (similar to SSRIs but without the 4–6 week onset delay). Enkephalinase inhibitor effect. Nootropic properties documented in clinical studies — improved memory, attention, and cognitive performance in anxious patients.

2015–present

Selank adopted by international biohacking and performance community for anxiety management without pharmaceutical side effects, cognitive enhancement, and nootropic stacking. Intranasal formulation developed — bypasses peptide degradation in GI tract, allows convenient dosing. Widely available as research compound internationally.

03 / BENEFITS

Primary Effects

01

Anxiolytic — Anxiety Reduction Without Sedation

Selank reduces anxiety with clinical efficacy comparable to benzodiazepines but with zero sedation, zero cognitive impairment, and zero addiction potential. Mechanism: GABA-A receptor stabilization + serotonin modulation + enkephalin system activation. Users describe a calm, clear-headed state — "relaxed focus" — as opposed to the foggy sedation of benzodiazepines.

02

Cognitive Enhancement — Memory & Learning

Selank's nootropic effects are documented: improved short-term memory consolidation, faster information processing, enhanced focus and attention. Mechanism: BDNF upregulation (neuroplasticity) + catecholamine optimization + reduced neuroinflammation. Paradoxically, reducing anxiety alone improves cognitive performance significantly — the anxiolysis and nootropic effects are synergistic.

03

BDNF Upregulation (Neuroplasticity)

Brain-Derived Neurotrophic Factor is the primary neuroplasticity signal — it drives synaptic formation, learning, memory, and neuronal survival. Selank increases BDNF expression, making it one of the few compounds with a clear neuroplasticity mechanism. Relevant for cognitive aging, learning optimization, and depression (low BDNF is a key feature of depression).

04

Anti-Depressant Activity

Selank demonstrates antidepressant effects in clinical studies — comparable to standard antidepressants but with rapid onset (days vs. 4–6 weeks for SSRIs). Mechanism: serotonin transporter modulation + BDNF upregulation + enkephalin system activation. No sexual side effects, no weight gain, no emotional blunting — key advantages over pharmaceutical antidepressants.

05

Immune Modulation (Tuftsin Base)

The tuftsin core of Selank retains immunomodulatory activity. Modulates IL-6 and IL-2 production, activates phagocytosis, and has antiviral properties. Russian clinical data suggests benefits for recurrent viral infections in immune-compromised individuals. Relevant context: Selank was also studied for HIV patients in Russia.

04 / RECONSTITUTION

Preparation Protocol

// 10MG VIAL — STANDARD RECONSTITUTION

10,000 mcg ÷ 300 units BAC water = 33.3 mcg per unit

Add 3.0 mL (300 units) bacteriostatic water to 10mg lyophilized vial.

TARGET DOSE	UNITS TO DRAW	VOLUME	NOTE
LOW250 mcg	7.5 units	0.075 mL	Sensitive users; mild anxiolytic
STANDARD500 mcg	15 units	0.15 mL	Standard anxiolytic + nootropic dose
HIGH1,000 mcg	30 units	0.30 mL	GAD clinical trial dose; upper range

Storage: Lyophilized — refrigerate (2–8°C), protect from light. Reconstituted: refrigerate, use within 30 days.

Intranasal Alternative: Many users prefer intranasal administration (nasal spray formulation). 100–300mcg per nostril, 1–2× daily. Bypasses first-pass metabolism, rapidly crosses BBB via olfactory route. If using reconstituted solution intranasally — ensure it's sterile and use appropriate nasal spray bottle.

05 / DOSING PROTOCOL

Administration Guide

PROTOCOL	DOSE	FREQUENCY	DURATION	CONTEXT
COGNITIVE	250–500 mcg SC	1–2×/day (AM + midday)	5 days on / 2 off	Focus, learning, nootropic effects
ANXIOLYTIC	500–1000 mcg SC	1–2×/day	4–8 weeks	GAD, social anxiety, performance anxiety
ACUTE STRESS	500 mcg SC/IN	Single dose PRN	As needed	Pre-presentation, high-stress events
STACK	250 mcg SC	With Semax AM	Ongoing	Selank (anxiolytic) + Semax (stimulating) balance

Classic Stack — Selank + Semax: Selank in the evening (anxiolytic, promotes calm) + Semax in the morning (stimulating, focus-enhancing) = comprehensive cognitive/mood optimization across the day. Widely used in Russian medicine and the international nootropic community.

06 / TIMING

Administration Timing

PREFERRED WINDOW

Morning or early afternoon for cognitive/focus effects. Evening for anxiety management and sleep preparation. Acute dosing: 30–60 min before stressful event.

ONSET

SC: 15–30 minutes. Intranasal: 5–15 minutes (faster BBB penetration via olfactory pathway). Effects last 4–6 hours from a single dose.

FOOD STATE

No significant food interaction. Can be taken fed or fasted. Some users prefer fasted for faster onset.

CYCLING

5 days on / 2 days off prevents tolerance accumulation. Some users run 4 weeks on / 1 week off. No withdrawal syndrome documented even with extended continuous use.

07 / BIOMARKERS

Monitoring Panel

// COGNITIVE & NEUROLOGICAL FUNCTION

MARKER	TEST	CLINICAL RANGE	OPTIMAL ON SELANK
BDNF (Serum)Brain-Derived Neurotrophic Factor	Specialty lab	CLIN8–32 ng/mL (serum)	OPTUpper-normal or above; increasing trend on Selank
Cognitive AssessmentSubjective + Objective	CNS Vital Signs, ImPACT, or Cambridge Cognition	CLINAge-normalized baseline	OPTImproved processing speed, memory, and attention vs. baseline

// MOOD & STRESS AXIS

MARKER	TEST	CLINICAL RANGE	OPTIMAL
AM CortisolStress Axis Function	AM serum (8 AM)	CLIN6–23 mcg/dL	OPT10–18 mcg/dL (robust AM peak; not suppressed)
GAD-7 Anxiety ScoreValidated Anxiety Scale	Self-reported questionnaire	CLIN0–4 = minimal; 5–9 = mild; 10+ = moderate-severe	OPT0–4 (minimal) — expected response to Selank in GAD
Serotonin (whole blood)Serotonin Activity Proxy	Specialty lab	CLIN50–220 ng/mL	OPTUpper-normal range (Selank modulates serotonin transporter)

08 / CYCLE PROTOCOL

Recommended Cycle

4–8

WEEKS ACTIVE

5 on/2 off

SCHEDULE

1–2

WEEKS OFF

500 mcg

STANDARD DOSE

Standard Protocol: 500mcg SC or intranasal, 1–2× daily, 5 days on / 2 days off. Run for 4–8 weeks then 1–2 weeks off. BDNF upregulation builds cumulatively over weeks — benefits compound with consistent use.

Cognitive Enhancement Protocol: 250mcg SC AM + 250mcg SC or intranasal midday. Pair with learning-intensive work (language study, skill acquisition, exam preparation). The BDNF upregulation makes this period of accelerated neuroplasticity particularly valuable for embedding new skills.

Semax + Selank Combination: Semax 300mcg (AM, stimulating, ACTH-derived, focus-first) + Selank 500mcg (PM, anxiolytic, calming, GABA/serotonin). These two peptides are the "yin and yang" of Russian nootropic medicine — used together they provide full-spectrum cognitive and mood optimization without stimulant crash or sedative grogginess.

Research Compound Notice: Selank is an approved prescription drug in Russia (since 2002) with over 25 years of clinical use data. It has not been approved by the FDA. The Russian clinical data demonstrates excellent safety and efficacy for anxiety disorders. No serious adverse effects documented in clinical literature. Not for use during pregnancy. Consult a healthcare provider before use for any psychiatric condition.